Tag: Aspaveli
-
Sobi to Unveil New One-Year Data on pegcetacoplan’s Efficacy in C3G and IC-MPGN, Plus NASP Outcomes at ASN Kidney Week 2025
Overview of the Upcoming ASN Kidney Week Presentations Stockholm-based biopharmaceutical company Sobi is set to share new clinical data at ASN Kidney Week 2025, taking place from November 5–9. The presentations will focus on pegylated C3 inhibitor pegcetacoplan, marketed as Aspaveli in Europe and Empaveli in the U.S., exploring its one-year efficacy in two rare…
-
Sobi to Unveil One-Year Pegcetacoplan Data for C3G, IC-MPGN and NASP at ASN Kidney Week 2025
Overview: Sobi to Share New Pegcetacoplan Data at ASN Kidney Week 2025 Sobi, a global biopharmaceutical company focused on rare diseases, has announced that new data on pegcetacoplan will be presented at ASN Kidney Week 2025, taking place from November 5–9. The presentations will explore one-year efficacy data for pegcetacoplan in C3 glomerulopathy (C3G) and…
-
Sobi to Unveil One-Year Data on pegcetacoplan for C3G and IC-MPGN, Plus NASP Results at ASN Kidney Week 2025
Overview of the Upcoming ASN Kidney Week Presentations Biopharma company Sobi has announced that new data will be shared at ASN Kidney Week 2025, taking place November 5–9. The conference program includes one-year efficacy data for pegylated C3G therapy pegcetacoplan (marketed as Aspaveli/Empaveli) in two glomerular diseases—the rare kidney conditions C3 glomerulopathy (C3G) and primary…